Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
338 DKK | -2.87% | +11.55% | +170.40% |
04-17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
03-29 | Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. | CI |
Sales 2022 | 199M 28.76M 39.39M | Sales 2023 | 205M 29.57M 40.5M | Capitalization | 2.04B 294M 402M |
---|---|---|---|---|---|
Net income 2022 | 4M 577K 790K | Net income 2023 | -44M -6.35M -8.69M | EV / Sales 2022 * | - |
Net cash position 2022 | 2.52M 364K 498K | Net cash position 2023 | 386M 55.66M 76.26M | EV / Sales 2023 | 8.05 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-42.6
x | Employees | 220 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.58% |
1 day | -2.87% | ||
1 week | +11.55% | ||
Current month | +11.18% | ||
1 month | +11.92% | ||
3 months | +118.06% | ||
6 months | +199.12% | ||
Current year | +170.40% |
Managers | Title | Age | Since |
---|---|---|---|
Niels Vrang
FOU | Founder | 56 | 07-12-31 |
Henrik Blou
CEO | Chief Executive Officer | 45 | 16-05-31 |
Kristian Borbos
DFI | Director of Finance/CFO | 46 | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 58 | 21-12-31 | |
Director/Board Member | 48 | 21-12-31 | |
Jacob Jelsing
FOU | Founder | 50 | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 338 | -2.87% | 53,145 |
24-05-07 | 348 | +12.62% | 194,493 |
24-05-06 | 309 | +3.00% | 37,138 |
24-05-03 | 300 | +1.35% | 11,380 |
24-05-02 | 296 | -2.31% | 17,434 |
Delayed Quote Nasdaq Copenhagen, May 08, 2024 at 10:59 am
More quotes1st Jan change | Capi. | |
---|---|---|
+170.40% | 793M | |
+2.93% | 108B | |
+8.82% | 105B | |
+1.54% | 23.46B | |
-14.60% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-8.83% | 17.19B | |
+5.51% | 13.99B | |
+37.49% | 12.53B |
- Stock Market
- Equities
- GUBRA Stock